AHLA. LL. Out in the Sunshine How to Protect Yourself
|
|
- Brendan Parker
- 5 years ago
- Views:
Transcription
1 AHLA LL. Out in the Sunshine How to Protect Yourself Jolee Hancock Bollinger General Counsel Franciscan Missionaries of Our Lady Health System Baton Rouge, LA Andrew D. Ruskin Morgan Lewis & Bockius LLP Washington, DC Physicians and Hospitals Law Institute February 5-7, 2014
2 overview Implications of the Sunshine Act for Hospitals: Manufacturer-Physician Relationships under the Microscope Physicians and Hospitals Law Institute February, 2014 Andrew Ruskin, Partner Morgan, Lewis & Bockius, Washington, DC Conflict of Interest Examples Prompting Legislative and Regulatory Action (2000) Jesse Gelsinger dies after receiving experimental gene therapy. Non-disclosure of a purported conflict of interest due to ownership by one of the clinical trial investigators in a biotech company. Lawsuit against numerous parties based in part on this nondisclosure, with claim that the omission was a fraudulent representation. The case settled out of court. (2007) Study published in NEJM shows that 94% of physicians have a financial relationship with manufacturers, e.g., gifts, compensation, etc. 2 1
3 Conflict of Interest Examples Prompting Legislative and Regulatory Action (cont.) ( ) Many stories of researchers failing to disclose outsized manufacturer payments they received to their employers, including employees of Stanford, Harvard, and Emory. (2011) Dr. Vishal James Makker is alleged to have performed repeated, unnecessary spine surgeries, while receiving over $500K per year from his physician-owned distributorship. Numerous settlements with drug and device manufacturers accused of violating the Anti Kickback Statute with purportedly excessive consulting fees for little to no work, CME trips to vacation spots, and other value adds. 3 Timeline of Major Legislative and Regulatory Developments Expansion of the Anti-Kickback Statute, originally enacted in Senator Grassley introduces the original version of the Sunshine Act, which was reintroduced in OIG begins to require disclosures as part of CIAs, totaling approximately 13 companies Affordable Care Act is passed, including Sunshine Act provisions. Aug., Revised PHS FCOI rules promulgated. Dec., CMS publishes Sunshine Act proposed rule. Feb., CMS publishes Sunshine Act final rule. 4 2
4 Sunshine Act Key concepts: Who does it apply to? What compensation disclosure requirements are there? How is research different? What ownership disclosure requirements are there? What is the disclosure process? What are the penalties? 5 Sunshine Act (cont.) Who will be interested in the information? Reporters. Competitors. OIG. Plaintiffs attorneys, including, possibly, relators counsel. Patient interest is likely to be tepid. 6 3
5 Sunshine Act (cont.) Potential consequences to hospitals: Bad press. Bad facts in a malpractice claim. OIG investigation. False Claims Act exposure. Loss of government research funding. Dissension among the medical staff. 7 Sunshine Act (cont.) Applicability. Reporting entities include applicable GPOs and applicable manufacturers. Applicable GPO means an entity that purchases, or arranges for the purchase of, a covered product, not solely for the GPO s own use. Applicable manufacturer means an entity that produces, prepares, propagates, compounds, or converts a covered product, unless solely for such entity s own use. 8 4
6 Sunshine Act (cont.) Applicability (cont.) Covered drug, device, biological, or medical supply is essentially any product that is either a prescribed drug or an FDA cleared or approved device. Also required to be reimbursed under Title XVIII or XIX. Covered recipients include physicians (except manufacturer employees) and teaching hospitals. Residents exempted, but fellow are not. There is a question as to whether a teaching hospital is defined by its TIN, irrespective of whether that includes the rest of the university. 9 Sunshine Act (cont.) Compensation disclosure. Applies only to applicable manufacturers, not GPOs. Includes direct and indirect transfers of value. Transfers of value need not relate to a specific product, except in certain limited circumstances. Manufacturers with less than 10% of their revenue attributable to covered products. Entities under common ownership that provide assistance or support in the sale of a product. A separate business line not independently manufacturing product. A contract manufacturer that does not hold FDA approval. 10 5
7 Sunshine Act (cont.) Compensation disclosure. (cont.) For each covered recipient, the following information is furnished: Name. Address. NPI, specialty, and State license number. Amount of transfer of value. Date of transfer. Form of payment. Nature of payment. 11 Sunshine Act (cont.) Compensation disclosure. (cont.) For each covered recipient, the following information is furnished (cont.): Covered product (if applicable). Eligibility for delayed publication (if research). Payment to third parties for covered recipient. Indication of whether recipient is an owner. (Optional) contextual information. 12 6
8 Sunshine Act (cont.) Compensation disclosure. (cont.) Acceptable form of payment identifiers: Cash or cash equivalent In-kind item or services Ownership interest Return on investment 13 Sunshine Act (cont.) Compensation disclosure. (cont.) Acceptable nature of payment identifiers: Consulting fee. Fee for other type of service. Honoraria. Gift. Entertainment. Food and beverage. Travel and lodging. Education. Research. 14 7
9 Sunshine Act (cont.) Compensation disclosure. (cont.) Acceptable nature of payment identifiers: (cont.) Charitable contribution. Royalty or license. Ownership interest. Compensation for speaking at a non-certified continuing education program. Compensation for speaking at a certified continued education program. Grant. Space rental or facility fees. 15 Sunshine Act (cont.) Compensation disclosure. (cont.) Special rules for continuing education and food and beverages apply. Research funding disclosure is distinct. Research payment disclosure can be postponed for up to 4 years. Any value not included as part of protocol will still be reported, but not as research. 16 8
10 Sunshine Act (cont.) Compensation disclosure. (cont.) Reporting exclusions: Indirect transfers of value where the applicable manufacturer is unaware of the identity of the covered recipient. Transfers of value of less than $10 (not to exceed $100 in the aggregate over a year). Product samples and coupons intended for patient use. Educational materials that directly benefit patients. The loan of a covered device for a short term trial period, not to exceed 90 days. Items or services under warranty. 17 Sunshine Act (cont.) Compensation disclosure. (cont.) Reporting exclusions: (cont.) Discounts. In-kind items used for charity care. Dividends on publicly traded stocks. Payments exclusively related to a legal or administrative proceeding. Transfers of value in the context of a personal relationship. Not excluded are payments for items purchased from teaching hospital. 18 9
11 Sunshine Act (cont.) Ownership disclosure. Disclosable ownership interests Reportable by both manufacturers and GPOs, and applies only to physicians and their family members. Includes: Physician name. Address. Specialty, NPI, and State license number. Dollar amount of investment. Current value and terms of ownership interest. Direct and indirect transfers of value to such physicians, or transfers of value made on behalf of such physicians 19 Sunshine Act (cont.) Reports follow a specific timeline. Reports are to be submitted by the 90th calendar day each year. Attestation required. Reporting entities may file a voluntary reasonable assumptions letter. CMS notifies covered recipients regarding the availability of the information for review. 45 day review period, plus an addition 15 days to resolve any disputes. OPEN PAYMENTS will make data publicly available September 30. Disputes not timely resolved result in CMS indication in the data that it is the subject of a dispute, and later corrections are included when data updated annually
12 Sunshine Act (cont.) Penalties. Failure to report (without scienter) results in fines of up to $10,000 per instance, with a cap of $150,000. Failure to report (with scienter) results in fines of up to $100,000 per instance, with a cap of $1,000, Public Health Service FCOI Regulations Reporting chain is investigator hospital Public Health Service. Investigators must disclose significant financial interests to their institutions, and update this disclosure within 30 days of any new significant financial interests
13 Public Health Service FCOI Regulations (cont.) Any financial interest that reasonably relates to the investigator s institutional responsibilities, irrespective of whether it relates to any PHS-funded research. Specifically included are: Receipt of value from any entity that exceeds $5000 in value. Ownership interest in a publicly traded entity of at least $5000, and in a privately held entity of any value. Value received from intellectual property rights. Excluded from disclosure are salary payments and certain other payments, such as payments for presenting at certain conferences. 23 PODs Typical structure: Physician-owned. Revenue derived from sales by POD to entities where physicianowners will perform services using goods sold by POD. Particular concern with implantable devices, which are often considered physician preference items chosen by physicians, rather than hospitals
14 PODs (cont.) Risk factors include: Selecting investors because of their ability to generate business. Requiring investors not using POD goods to divest their ownership interests. Distributing returns on investment disproportionate to the level of risk involved. Physician-owner referrals to hospital are contingent on POD purchases. Evidence that the PODs are sham businesses with no value additivity. 25 Out in the sunshine How to protect yourself Jolee Hancock Bollinger General Counsel 13
15 Franciscan Missionaries of Our Lady Health System 27 Media Reports Neurosurgeon Adam Lewis at his Jackson, MS office. The Clarion-Ledger 28 14
16 Widespread Relationships Discovered Reports on Employed Physicians Continued Focus on Physician Acquisitions Physician Preference Items Growth of Research Minimal Knowledge on Independent Physicians 29 Open Payments Reputation Risk Liability Risk Board/Executive Interests How to MITIGATE RISKS?
17 Steps Taken Discussed Issues in Terms of Best Patient Care Informal Meetings to Discuss Issues Identify Physician Champions Develop Conflict Policy Through Collaboration 31 Goals of Conflict Policy Overriding Goal of Best Patient Care Balanced Competing Interests Benefits resulting from physician knowledge and collaboration Financial incentives leading to treatment bias Mitigate risks Reputation risks Liability risks 32 16
18 Conflict of Interest Policy Topics Addressed Gifts Personal Donations of Equipment Monetary Donations Meals On-site Off-site Prescription Drug Samples Hospitals Clinics 33 Conflict of Interest Policy Topics Addressed Travel Paid By Industry Industry Representative Access Industry Sponsored Scholarships and Other Educational Funds Participation in Industry Sponsored Programs Industry Marketing Agreements/Contracts with Third Parties Honorarium from Continuing Education Events Research 34 17
19 Continuing Questions/Issues Employed vs. Non-Employed Physicians Implementation 35 How to Review Reports? Register with Open Payments Vendor Websites Work with manufacturers and GPOs to review information before it is sent to CMS Request review of data before reporting Provide opportunity to correct reported data Add statement describing context of payment 36 18
20 Education Physicians were advised to: Download App for Tracking Assistance Search Open Payments in App Store 37 Public Health Service FCOI Regulations (cont.) Each institution subject to the rule must have and enforce a financial conflict of interest policy that it uses to educate its physicians and makes available on its website. Institutions must designate an institutional official to review investigator disclosures. Institutions must determine whether any significant financial interest could directly and significantly affect the design, conduct, or reporting of the PHS funded research
21 Public Health Service FCOI Regulations (cont.) Institutions must manage any financial conflicts of interest, including through disclosure, monitoring, or divestiture. Website disclosures of significant financial interests, including their amount, must also be made. The amounts can be in ranges (e.g., $0-$4,999, $5,000 to $9,999, etc.). Institutions must provide reports to the Public Health Service, and they must certify compliance with every application for PHS funding. Failure to adhere to these requirements could lead to sanctions, including suspension of PHS funding. 39 Public Health Service FCOI Regulations (cont.) Other agencies FCOI policies to consider include: FDA NIH OHRP Voluntary guidelines from AAMC and others are also available
22 Clinical Trial Reimbursement Important billing compliance obligations are found in these policies. Failure to have complied with the applicable requirements means that the claims were not properly payable. Hospitals learning through Sunshine Act disclosure that members of their medical staff had been receiving research funding may trigger a need to determine if billing had been compliant. 41 Clinical Trial Reimbursement (cont.) Medicare Clinical Trial Policy Clinical trial requirements. Must involve the evaluation of an item or service that falls within a Medicare benefit category. Test must have a therapeutic intent. Must enroll patients with diagnosed disease rather than healthy volunteers if therapeutic intervention. Diagnostic tests can have a control group
23 Clinical Trial Reimbursement (cont.) Medicare Clinical Trial Policy (cont.) Must be good science, which is deemed to be true for: Trials funded by NIH, CDC, AHRQ, CMS, DOD, or VA. Includes trials supported by centers or groups funded by any of these agencies. Trials conducted under an IND reviewed by the FDA. Trials exempt from an IND. 43 Clinical Trial Reimbursement (cont.) Medicare Clinical Trial Policy (cont.) Exclusions from payment include: The investigational item itself. Data collection not directly related to clinical management. Items and services customarily provided by research sponsors free of charge to any enrollee in the trial
24 Clinical Trial Reimbursement (cont.) Medicare Clinical Trial Policy (cont.) Billing. Paid for consistent with existing systems (DRG, APC, etc.). Use condition code 30 for all claims. Use diagnosis code V70.7 for healthy control group individuals. Use diagnosis code V70.7 as secondary diagnosis for all patients receiving treatment. For services billed on a CMS 1500, use modifier Q1 next to services that are routine care furnished to individuals in qualifying trial and Q0 for investigational items. Medical record requirements also apply. 45 Clinical Trial Reimbursement (cont.) Investigation Device Policy. Coverage of Category A devices. Routine costs covered, but not the device itself, provided that: Involves the diagnosis, monitoring, or treatment of a life-threatening disease. Provider furnishes information regarding clinical trial to contractor. Meets yet undetermined scientific and ethical standards to be established by CMS. Must be medically necessary for given patient
25 Clinical Trial Reimbursement (cont.) Investigation Device Policy. (cont.) Otherwise Category A devices, and services that are incident to the device, such as preparatory services and after-care, are not covered. Coverage of Category B devices. Routine care is covered. Must be in an FDA-approved clinical trial. Must be medically necessary for given patient. 47 Clinical Trial Reimbursement (cont.) Investigation Device Policy. (cont.) Billing. Before billing, must submit to Medicare Contractor: A copy of the FDA-approval letter. Device name. Applicable IDE special controls implemented. A narrative description of the device. A statement indicating how the device is similar to and/or different from other comparable products. Indication of whether the device will be billed on an inpatient or outpatient claim. Summary of the study design or copy of trial protocol. Informed consent process
26 Clinical Trial Reimbursement (cont.) If the first time a hospital learns of a physician s use of an investigational item is after a Sunshine Act disclosure, then it is too late. 49 Precautionary Steps Disclosure Response policy Need a dispute resolution policy, including when will require medical staff to dispute Need reasonable assumptions letters Need to establish criteria for which discrepancies between physician disclosures and Sunshine Act reports will trigger further investigation Determine the parameters of all such investigations. Performed by Compliance? Legal? What due process is given the physician? Range of consequences? Need to be able to explain to public why PHS and Sunshine Act are different 50 25
27 Precautionary Steps (cont.) Research policy Need to be clear about how clinical trial dollars will be treated by sponsor Vendor Procurement policy Ensure that hospital s policy with respect to procurement of physician preference items is insulated from conflicts of interest Be conservative in terms of deciding which vendors will be subject to policy Consider Sunshine Act issues when deciding whether to start taking GME payments 51 26
FACT SHEET. The Physician Payments Sunshine Act: CMS Proposed Rule
FACT SHEET The Physician Payments Sunshine Act: CMS Proposed Rule Executive Summary: CMS is making rules to implement sections of the Patient Protection and Affordable Care Act that would require eye banks
More informationThe Physician Payments Sunshine Law and you: Building stronger industry - physician interactions
The Physician Payments Sunshine Law and you: Building stronger industry - physician interactions 1 What is the timing of the Sunshine Law requirements? Aug. 1, 2013: Manufacturers are required to begin
More informationAssociation of Corporate Counsel January 2012 Teleconference CMS Finally Issues Proposed Sunshine Act Regulations
1 Association of Corporate Counsel January 2012 Teleconference CMS Finally Issues Proposed Sunshine Act Regulations January 3, 2012 Judy Waltz, Partner Foley & Lardner LLP 2012 Foley & Lardner LLP Attorney
More informationSIDE-BY-SIDE OF THE PHYSICIAN PAYMENTS SUNSHINE ACT
Provision Amends Implementation Date Who must disclose? Reporting Frequency Grassley 2008 bill Grassley/Kohl bill Patient Protection and revised (S.301), 111 th Affordable Care Act (MAL08221) Congress
More informationFOR PHYSICIANS. CMS will collect the data annually, aggregate it, and publish it on a public website.
Open Payments (Physician Payments Sunshine Act) Why Open Payments is Important to You Section 6002 of the Affordable Care Act requires the establishment of a transparency program, now known as Open payments.
More informationPHYSICIAN PAYMENTS SUNSHINE ACT (OPEN PAYMENTS) Mary Evelyn Armstrong MA, CRA Conflict of Interest Officer
PHYSICIAN PAYMENTS SUNSHINE ACT (OPEN PAYMENTS) Mary Evelyn Armstrong MA, CRA Conflict of Interest Officer WHAT IS IT? Section 6002 of the Affordable Care Act requires the establishment of a transparency
More informationWeb Seminar. Physician Payments in the "Sunshine": Implications of CMS Regulations for Business and the Future of American Health Care.
Web Seminar Physician Payments in the "Sunshine": Implications of CMS Regulations for Business and the Future of American Health Care Featuring James C. Stansel Sidley Austin LLP Meenakshi Datta Sidley
More informationKnow, Prepare and Comply with the Sunshine Act Phase 2. John A. Murphy, III, Assistant General Counsel PhRMA August 26, 2014
Know, Prepare and Comply with the Sunshine Act Phase 2 John A. Murphy, III, Assistant General Counsel PhRMA August 26, 2014 Sponsored by: HCIdea provides the most accurate Physician data (NPIs and State
More informationShedding Light on the Sunshine Act
Shedding Light on the Sunshine Act February 28, 2013 Jean C. Hemphill hemphill@ballardspahr.com 215.864.8539 Mary J. Mullany mullany@ballardspahr.com 215.864.8631 Copyright 2013 by Ballard Spahr LLP Program
More informationPhysician Payments Sunshine Act Proposed Rule Published
Physician Payments Sunshine Act Proposed Rule Published Kim Kannensohn Krist Werling Holly Carnell www.mcguirewoods.com McGuireWoods news is intended to provide information of general interest to the public
More informationUnderstanding the Forces Driving Disclosure
Understanding the Forces Driving Disclosure March 3, 2010 Jeffrey L. Handwerker Forces Behind the Trend Toward Disclosure State Laws/Legislatures/NLARx Academic Institutions Voluntary Changes in Company
More informationPhysician Payment Sunshine Provisions in Healthcare Reform Prepared by AAMC Government Relations Revised May 28, 2010
Physician Payment Sunshine Provisions in Healthcare Reform Prepared by AAMC Government Relations Revised May 28, 2010 Section 6002 of the Patient Protection and Affordable Care Act [P.L. 110-148] amends
More informationCENTERS FOR MEDICARE & MEDICAID SERVICES (CMS) OPEN PAYMENT FREQUENTLY ASKED QUESTIONS (FAQ) TRACKER
CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS) OPEN PAYMENT FREQUENTLY ASKED QUESTIONS (FAQ) TRACKER Current as of 12, attorney advertisement Cooley LLP Five Palo Alto Square, 3000 El Camino Real, Palo
More informationPhysician Payments Sunshine Act Final Rule ACA Section 6002
Physician Payments Sunshine Act Final Rule ACA Section 6002 Program Overview Applicable manufacturers and applicable GPOs collect information on payments and/or ownership interests for an entire calendar
More informationFINANCIAL DISCLOSURES AND CONFLICTS OF INTEREST IN CLINICAL RESEARCH
FINANCIAL DISCLOSURES AND CONFLICTS OF INTEREST IN CLINICAL RESEARCH Richard S Liner, JD Ronald H. Clark, PhD, JD Arent Fox Kintner Plotkin & Kahn, PLLC Washington D.C./New York 1 In light of the expansion
More informationTransparency reports (Sunshine Act)
Transparency reports (Sunshine Act) Summary: Requires drug, device, biological and medical supply manufacturers to report transfers of value made to a physician or a teaching hospital. Duplicative State
More informationIn this course, we will cover the following topics: The structure and purpose of Navicent Health s Compliance Program The requirements of the
In this course, we will cover the following topics: The structure and purpose of Navicent Health s Compliance Program The requirements of the Navicent Health s Corporate Integrity Agreement (CIA) Your
More informationHCCA CLINICAL PRACTICE COMPLIANCE CONFERENCE
HCCA CLINICAL PRACTICE COMPLIANCE CONFERENCE CMS Open Payments Formerly Known as the Sunshine Act October 13, 2014 Philadelphia, Pennsylvania PRESENTATION OBJECTIVES Open Payment Regulations Reporting
More informationKEY CHANGES IN THE FINAL PHYSICIAN PAYMENT SUNSHINE ACT REGULATIONS. Association of Corporate Counsel Legal Quick Hit May 30, 2013.
1 KEY CHANGES IN THE FINAL PHYSICIAN PAYMENT SUNSHINE ACT REGULATIONS Association of Corporate Counsel Legal Quick Hit May 30, 2013 Maria E. Gonzalez Knavel Partner Foley & Lardner LLP 414.297.5649 mgonzalezknavel@foley.com
More informationCoverage and Billing Issues for Clinical Research
Coverage and Billing Issues for Clinical Research John E. Steiner, Jr., Esq Chief Compliance Officer Cleveland Clinic Health System Cleveland, Ohio The Second Annual Medical Research Summit Washington,
More informationTitle Final Sunshine Act Arrives: Now the Hard Part
Title Final Sunshine Act Arrives: Now the Hard Part January 2013 March 2013 www.morganlewis.com 1 2013 Morgan, Lewis & Bockius LLP The Centers for Medicare and Medicaid Services (CMS) issued the final
More informationANCILLARY services: How to Stay Out of Trouble. The neurosurgical minefield Informed consent
ANCILLARY services: How to Stay Out of Trouble Richard N.W. Wohns, M.D. JD, MBA NeoSpine, Puget Sound Region, Washington The neurosurgical minefield 2013 Informed consent HIPAA ARRA and HITECH Anti-Kickback
More informationPolicy Number: Location: Origination Date: Date of Last Review: Baylor Research Institute 8/24/2012 7/11/2012
Policy Name: Financial Conflict of Interest in Research Policy Department/Service Line: Research Subject Protection Policy Number: BHCS.BRI.SP.811.P.V12 Location: Origination Date: Date of Last Review:
More informationCENTERS FOR MEDICARE & MEDICAID SERVICES (CMS) OPEN PAYMENT FREQUENTLY ASKED QUESTIONS (FAQ) TRACKER. June attorney advertisement
CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS) OPEN PAYMENT FREQUENTLY ASKED QUESTIONS (FAQ) TRACKER June 2014 attorney advertisement 2014 Cooley LLP Five Palo Alto Square, 3000 El Camino Real, Palo Alto,
More informationPhysician Payment Transparency Provisions of the Affordable Care Act Sunshine 101
Physician Payment Transparency Provisions of the Affordable Care Act Sunshine 101 Danielle Drissel, Associate February 19, 2013 Health/ Washington DC What is Sunshine? Deceptively simple: Applicable manufacturers
More informationWelcome to the Lex Mundi Learning Network. Understanding the New U.S. Sunshine Act and Its Impact on Health Care Providers and Industry
Welcome to the Lex Mundi Learning Network Understanding the New U.S. Sunshine Act and Its Impact on Health Care Providers and Industry Colin Zick, Foley Hoag LLP Pat Cerundolo, Foley Hoag LLP Bill McKenzie,
More informationMEMORANDUM. Bob Saner, MGMA Washington Counsel and Johanna Michaels Kreisel, Attorneys in the Powers Law Firm
MEMORANDUM To: From: MGMA Bob Saner, MGMA Washington Counsel and Johanna Michaels Kreisel, Attorneys in the Powers Law Firm Date: May 1, 2013 Re: Final Rule Implementing the Physician Payments Sunshine
More informationUNIVERSITY OF WISCONSIN-STEVENS POINT OFFICE OF RESEARCH AND SPONSORED PROGRAMS
UNIVERSITY OF WISCONSIN-STEVENS POINT OFFICE OF RESEARCH AND SPONSORED PROGRAMS FINANCIAL CONFLICTS OF INTEREST POLICY FOR PUBLIC HEALTH SERVICE (PHS)-FUNDED PROJECTS The University of Wisconsin-Stevens
More informationCigna Administrative Policy
Cigna Administrative Policy Subject Clinical Trials Table of Contents Administrative Policy... 1 General Background... 2 Coding/Billing Information... 4 References... 4 Effective Date... 1/15/2014 Administrative
More informationTHE LINK BETWEEN FDA APPROVAL OF MEDICAL DEVICES AND REIMBURSEMENT
1 THE LINK BETWEEN FDA APPROVAL OF MEDICAL DEVICES AND REIMBURSEMENT Association of Corporate Counsel Legal Quick Hit September 6, 2011 Maria E. Gonzalez Knavel Partner Foley & Lardner LLP 414.297.5649
More informationGifts to Referral Sources. Kim C. Stanger (11-17)
Gifts to Referral Sources Kim C. Stanger (11-17) Overview Some relevant laws Applying those laws to common situations Gifts to or from referral sources Gifts to physicians Gifts to or from patients Gifts
More informationPPACA and Physicians: Payment, Quality, Program Integrity
PPACA and Physicians: Payment, Quality, Program Integrity Mary Patton mpatton@aamc.org Ivy Baer ibaer@aamc.org Dave Moore dbmoore@aamc.org AAMC Teleconference April 27, 2009 Agenda Physician Payment &
More informationFrequently Asked Questions
Medical Imaging and Technology Alliance (MITA) Fact Sheet on Federal and State Medical Device Marketing or Sunshine Disclosure Laws Updated November 16, 2011 A new federal law called the Federal Physician
More informationConflicts of Interest
Conflicts of Interest What happens when what is reported to you does not match what is reported by or to others. HCCA Compliance Institute April 22, 2013 Session 111 Marti Arvin, Chief Compliance Officer,
More informationCENTERS FOR MEDICARE & MEDICAID SERVICES (CMS) OPEN PAYMENT FREQUENTLY ASKED QUESTIONS (FAQ) TRACKER
CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS) OPEN PAYMENT FREQUENTLY ASKED QUESTIONS (FAQ) TRACKER Current as of 12, attorney advertisement Cooley LLP Five Palo Alto Square, 3000 El Camino Real, Palo
More informationManufacturer Patient Support Initiatives: Current Practices and Recent Challenges. Andrew Ruskin Morgan Lewis
Intersecting Worlds of Drug, Device, Biologics and Health Law AHLA/FDLI May 22, 2012 Manufacturer Patient Support Initiatives: Current Practices and Recent Challenges by Andrew Ruskin Morgan Lewis The
More informationClinical Trials Corporate Medical Policy
Clinical Trials Corporate Medical Policy File name: Clinical Trials File code: UM.GEN.02 Origination: 12/31/2013 Last Review: 03/2017 Next Review: 03/2018 Effective Date: 06/01/2017 Description This medical
More informationIndustry Funding of Continuing Medical Education
Industry Funding of Continuing Medical Education June 25, 2010 Julie K. Taitsman, M.D., J.D. Chief Medical Officer, Office of Inspector General U.S. Department of Health and Human Services Financial Relationships
More informationShedding Light on the U.S. and French Sunshine Laws
Shedding Light on the U.S. and French Sunshine Laws Teleseminar September 17, 2014 Elizabeth Carder-Thompson, Washington, D.C. & Princeton, N.J. Daniel Kadar, Paris Overview of Discussion Origins and implementation
More informationSunshine and Aggregate Spend
Sunshine and Aggregate Spend Challenges and Leading Practices in Reporting Clinical Spend Sixth Annual Summit on Disclosure, Transparency and Aggregate Spend for Drug, Device and Biotech Companies February
More informationMAIMONIDES MEDICAL CENTER SUBJECT: CONFLICTS OF INTEREST IN HUMAN RESEARCH & PHS FUNDED RESEARCH
MAIMONIDES MEDICAL CENTER CODE: RES-021 (Reissued) ORIGINALLY ISSUED: October 22, 2009 SUBJECT: CONFLICTS OF INTEREST IN HUMAN RESEARCH & PHS FUNDED RESEARCH I. POLICY Consistent with current law and to
More informationPOLICY NO.: BHSF POLICY TITLE: Individual Financial Conflicts of Interest (FCOI) in Research
A dm inis trative Departmental POLICY TITLE: Individual Financial Conflicts of Interest (FCOI) in Research SUMMARY & PURPOSE: The purpose of this policy and procedure is to promote objectivity in research
More informationThe Changing Landscape of Medicare's Clinical Trial Coverage Policies for Medical Devices. Michael Sanchez, M.A., CCA Reimbursement Advisor
The Changing Landscape of Medicare's Clinical Trial Coverage Policies for Medical Devices Michael Sanchez, M.A., CCA Reimbursement Advisor Disclaimer The reimbursement information provided in this presentation
More informationLegal Considerations for Patient Assistance Programs
Legal Considerations for Patient Assistance Programs March 6, 2014 Robert D. Clark Ober Kaler (202) 326-5039 Seth H. Lundy King & Spalding (202) 626-2924 S. Craig Holden Ober Kaler (410) 347-7322 Topics
More informationGUIDANCE: Financial Conflicts of Interest NUMBER DATE AUTHOR APPROVED BY AUDIENCE USE PAGE
Page 1 of 5 1 PURPOSE 1.1 This guidance establishes the methodology by which (a) the Sharp HealthCare (SHC) Review Board (IRB) will require the reporting of personal and institutional financial interests
More informationLatham & Watkins Corporate and Litigation Departments. CMS Issues Proposed Regulations Interpreting the Physician Payment Sunshine Act
Number 1266 December 19, 2011 Client Alert Latham & Watkins Corporate and Litigation Departments CMS Issues Proposed Regulations Interpreting the Physician Payment Sunshine Act CMS estimates the average
More informationOpen Payments Law Overview. University of Alabama at Birmingham University Compliance Office
Open Payments Law Overview University of Alabama at Birmingham University Compliance Office What is the Open Payments Law? Federal law (formerly known as Physician Payment Sunshine Act ) signed into effect
More informationThe Physician Payment Sunshine Act Final Rule A Summary Of Key Provisions
The Physician Payment Sunshine Act Final Rule A Summary Of Key Provisions On February 1, 2013, Centers for Medicare and Medicaid Services (CMS) published the long-awaited Physician Payment Sunshine Act
More informationCMS ISSUES FINAL RULE FOR IMPLEMENTING SUNSHINE ACT. Executive Summary
WSGR ALERT FEBRUARY 2013 CMS ISSUES FINAL RULE FOR IMPLEMENTING SUNSHINE ACT On February 8, 2013, 16 months after the statutory deadline, the Centers for Medicare & Medicaid Services (CMS) published in
More informationSection 6004: Prescription Drug Sample Transparency. Section 6005: Pharmacy Benefit Managers Transparency Requirements
Legislative text of Physician Payment and other transparency provisions included in H.R. 0: Patient Protection and Affordable Care Act of 0 Passed by the Senate (//0) and the House (//) Section 00: Transparency
More informationFAST BREAK : HOLIDAY GIFTS Jake Harper December 18, Morgan, Lewis & Bockius LLP
FAST BREAK : HOLIDAY GIFTS Jake Harper December 18, 2018 2018 Morgan, Lewis & Bockius LLP Agenda Holiday Gifts and the Laws They May Trigger Stark Beneficiary Inducement CMP AKS One-purpose Test Considerations
More informationConflict of Interest Policy. Approved August 2012 Mayo Clinic Board of Governors
Conflict of Interest Policy Approved August 2012 Mayo Clinic Board of Governors Table of Contents I. Overview... 4 A. Guiding Principles... 4 B. What is a Conflict of Interest?... 4 C. What Can Cause a
More informationThis Financial Conflict of Interest Policy is designed to maintain the trust of the public, research volunteers and the University research community.
Financial Conflict of Interest Policy for Federal Research Grants Introduction This policy governing financial conflicts of interest (FCOI) applies to all Investigators at Taylor University who apply to
More informationNegotiating with Industry: What They Want vs. What We Need
Negotiating with Industry: What They Want vs. What We Need Presented At: Massachusetts General Hospital October 19, 2017 Presented By: Partners Clinical Trials Office Maureen Lawton, Pharm.D., J.D. Michael
More informationTo: Vice Chancellors, Deans, Administrative Staff, Department Heads, and Students.
Chancellor s Memorandum CM-35 Conflicts of Interest in Research: Managing Potential Financial and Non-Financial Conflicts of Interest of Individuals and the Institution To: Vice Chancellors, Deans, Administrative
More informationPharmaceutical Compliance Congress: State of the States
Pharmaceutical Compliance Congress: State of the States October 27, 2008 Janice G. Cunningham Jeffrey L. Handwerker Overview Types of State Laws Potentially Affected by the Sunshine Act Limits or Prohibitions
More informationAuburn University Procedures for Public Health Service Financial Conflicts of Interest Regulations
1 Auburn University Procedures for Public Health Service Financial Conflicts of Interest Regulations Introduction The Public Health Service (PHS) has issued its final rule entitled Responsibility of Applicants
More informationAnti-Kickback Statute Jess Smith
Anti-Kickback Statute Jess Smith Overview 1972 - Enacted 1977 - Violation became a felony 1996 - Expanded to include all Federal Health Care Programs 2009 - Health Care Fraud Prevention and Enforcement
More informationTitle: Previous Version(s): 8/01, 1/02, 6/06, 1/12, 4/12
Title: Financial Conflicts of Interest Department: Research Institute Effective Date: 3/18 Reviewed: Previous Version(s): 8/01, 1/02, 6/06, 1/12, 4/12 Policy & Procedure Replaces: Disclosure of Conflicts
More informationWHAT EVERY NEW PRACTITIONER SHOULD CONSIDER
WHAT EVERY NEW PRACTITIONER SHOULD CONSIDER January 24, 2017 Andrew N. Meyercord Gray Reed & McGraw 1601 Elm Street Suite 4600 Dallas, Texas 75201 214.954.4135 ameyercord@grayreed.com 129 attorneys Full-service,
More informationPhysician Payments Sunshine Provisions in Healthcare Reform Tracking and Monitoring Spending on Healthcare Professionals and Organizations
Physician Payments Sunshine Provisions in Healthcare Reform Tracking and Monitoring Spending on Healthcare Professionals and Organizations Background Consumer advocates and the media have commented in
More informationCONFLICTS OF INTEREST IN RESEARCH
IM&COI POLICY III CONFLICTS OF INTEREST IN RESEARCH (Capitalized terms are defined in the Glossary.) Presumption Against Participating in Research When Personal Financial Interests Exist If an Investigator
More informationPatient Protection and Affordable Care Act (P.L ) Titles VI through X
Patient Protection and Affordable Care Act (P.L. 111-148) Titles VI through X As enacted March 23, 2010 The following pages contain the text of Titles VI through X of the Patient Protection and Affordable
More informationAmerican Academy of Orthopaedic Surgeons 2010 Annual Meeting. March 12, 2010
American Academy of Orthopaedic Surgeons 2010 Annual Meeting March 12, 2010 Developments in the Evolving Orthopaedic Surgeon - Industry Relationship Kathleen McDermott, Esquire Washington, DC 1 Developments
More informationLSUHSC-NO Chancellor s Memorandum (CM-35)
LSUHSC-NO Chancellor s Memorandum (CM-35) Individual and Institutional Conflicts of Interest in Sponsored Projects Updated 4/26/2017 CM-35 An Investigator shall not be permitted to begin any research activity
More informationCoverage Analysis and Research Billing Beyond SOC vs. Study Paid. March 14, 2014
Coverage Analysis and Research Billing Beyond SOC vs. Study Paid March 14, 2014 Overview Laws and regulations for billing for patients in clinical trials CMS s National Coverage Decision, Affordable Care
More informationUniversity of New England Investigator Significant Financial Interest Disclosure Policy for Sponsored Projects Originally Adopted March 2005
University of New England Investigator Significant Financial Interest Disclosure Policy for Sponsored Projects Originally Adopted March 2005 Revised August 2012 Table of Contents Introduction... 3 Background...
More informationFrequently Asked Questions (FAQs) regarding the. National Physician Payment Transparency Program (Open Payments)
Frequently Asked Questions (FAQs) regarding the National Physician Payment Transparency Program (Open Payments) [initiated by the Physician Payments Transparency Act (PPSA)] These FAQs are intended as
More informationStandard Operating Procedures for Disclosure and Management of Financial Conflicts of Interest
Standard Operating Procedures for Disclosure and Management of Financial Conflicts of Interest Effective May 1, 2013 TABLE OF CONTENTS 1.0 GENERAL PRINCIPLES... 3 2.0 SCOPE... 3 3.0 GUIDING PRINCIPLES...
More informationUNDERSTANDING AND WORKING WITH THE LATEST STARK LAW DEVELOPMENTS
26 th Annual National CLE Conference Law Education Institute January 3-7, 3 2009 UNDERSTANDING AND WORKING WITH THE LATEST STARK LAW DEVELOPMENTS By JONELL B. WILLIAMSON January 5, 2009 1 Stark Prohibition
More informationClient Alert. CMS Announces Final Regulations Interpreting the Physician Payment Sunshine Act. A. Definitions and Exclusions
Number 1469 February 18, 2013 Client Alert Latham & Watkins Corporate Department CMS Announces Final Regulations Interpreting the Physician Payment Sunshine Act To avoid significant penalties for non-compliance,
More informationCompliance and Conflict of Interest for Researches Briefing (COIR)
Compliance and Conflict of Interest for Researches Briefing (COIR) Conflicts of Interest In the University research setting, financial conflicts of interest can be defined several ways. Having a financial
More informationCentral Office of Research Administration
SECTION: PURPOSE STATEMENT To set forth the process for reviewing financial interests, and for identifying and addressing financial conflicts of interest ( FCOI ) in Research (as defined later in this
More informationPartners In Health Financial Conflicts of Interest Policy
Partners In Health Financial Conflicts of Interest Policy In accordance with the requirements set forth by the Public Health Service (PHS),, Partners In Health (PIH) has established a Financial Conflict
More informationREGENERON PHARMACEUTICALS, INC. FINANCIAL CONFLICTS OF INTEREST POLICY FOR PHS-FUNDED RESEARCH
REGENERON PHARMACEUTICALS, INC. FINANCIAL CONFLICTS OF INTEREST POLICY FOR PHS-FUNDED RESEARCH I. INTRODUCTION This Financial Conflicts of Interest Policy for PHS-Funded Research ( FCOI Policy ) implements
More informationBill Moran and Betta Sherman
Compliance TODAY July 2013 a publication of the health care compliance association www.hcca-info.org How an eye doctor s son sees compliance an interview with Stephen Kiess Assistant General Counsel for
More informationOpen Payments An Explanation of Section 6002 of the Affordable Care Act
Open Payments An Explanation of Section 6002 of the Affordable Care Act Center for Program Integrity February, 2014 CMS Disclaimer: This information is a summary of sections of the NPPTP. This information
More informationJohnson & Johnson Financial Conflicts of Interest Policy
Johnson & Johnson Financial Conflicts of Interest Policy I. INTRODUCTION A. Purpose This policy implements U.S. federal requirements pertaining to Objectivity in Research promulgated by the Public Health
More informationRESPIRONICS, INC. CONTRACTING WITH HEALTHCARE PROFESSIONALS OR PROVIDERS AND REFERRAL SOURCES POLICY
Page 1 of 6 RESPIRONICS, INC. CONTRACTING WITH HEALTHCARE PROFESSIONALS OR PROVIDERS AND REFERRAL SOURCES POLICY I. Purpose This document sets forth Respironics, Inc. s ( Company ) policy for engaging
More informationAHLA. F. Anti-Kickback Primer. David E. Matyas Epstein Becker & Green PC Washington, DC
AHLA F. Anti-Kickback Primer David E. Matyas Epstein Becker & Green PC Washington, DC Martha J. Talley Chief, Industry Guidance Branch Office of the Inspector General US Department of Health and Human
More informationConflict of Interest (COI): What s All the Buzz About?
Conflict of Interest (COI): What s All the Buzz About? ACCR Lecture: 9/21/12 Julia M. Campbell Director, COI Topics for Discussion Impetus and environment prompting new COI regulations Case studies Overview
More informationCORPORATE COMPLIANCE: CONFLICT OF INTEREST
CORPORATE COMPLIANCE: CONFLICT OF INTEREST Conflict of Interest (CC1208) KEY WORDS: Disclosure of Financial Relationships, Conflict of Interest, Human Subjects Research OBJECTIVE/BACKGROUND: Board Members,
More informationSTATE TRANSPARENCY AND GIFT BAN STATUTES
ARTICLE 02 STATE TRANSPARENCY AND GIFT BAN STATUTES IN THIS ARTICLE: Federalism at Work The Challenge of Compliance Tips to Build Your Compliance Policy and Avoid Fines 2 STATE TRANSPARENCY AND GIFT BAN
More informationObjectivity in Research and Investigator Financial Disclosure
Objectivity in Research and Investigator Financial Disclosure Scope This policy applies to Mount Mary University employees who serve as investigators and who apply for funding through Mount Mary University
More informationFraud, Waste and Abuse: Compliance Program. Section 4: National Provider Network Handbook
Fraud, Waste and Abuse: Compliance Program Section 4: National Provider Network Handbook December 2015 2 Our Philosophy Magellan takes provider fraud, waste and abuse We engage in considerable efforts
More informationFINANCIAL CONFLICT OF INTEREST POLICY
FINANCIAL CONFLICT OF INTEREST POLICY Individuals who are appointed to serve on ABIM boards or committees are expected to have the American Board of Internal Medicine s (ABIM) mission as their primary
More informationLaw Department Policy No. L-8. Title:
I. SCOPE: Title: Page: 1 of 13 This policy applies to (1) Tenet Healthcare Corporation and its wholly-owned subsidiaries and affiliates (each, an Affiliate ); (2) any other entity or organization in which
More informationIs the Sunshine Act the. support? John P. Gonzalez Director of Publications Policy AstraZeneca
Is the Sunshine Act the twilight of pharmasponsored medical writing support? John P. Gonzalez Director of Publications Policy AstraZeneca Conflict of interest disclosure I am a full time employee of AstraZeneca
More informationFinancial Conflict of Interest Policy
NUMBER: 3.3 SECTION: Human Resources REVISION: V2 SUBJECT: Financial Conflict of Interest EFFECTIVE DATE: August 24, 2012 Financial Conflict of Interest Policy PURPOSE InterveXion Therapeutics ( InterveXion
More informationFinancial Conflict of Interest Policy and Procedural Manual
Financial Conflict of Interest Policy and Procedural Manual Financial Conflict of Interest... 1 Policy and Procedural Manual... 1 Financial Conflict of Interest Policy... 2 Disclosure of Financial Conflicts
More informationFRAUD AND ABUSE LAW IMPLICATED BY COMPENSATION ARRANGEMENTS. Lee Rosebush, PharmD, RPh, MBA, JD
FRAUD AND ABUSE LAW IMPLICATED BY COMPENSATION ARRANGEMENTS Lee Rosebush, PharmD, RPh, MBA, JD lrosebush@bakerlaw.com Real Quick Overview False Claims Act Any person who knowingly presents, or causes to
More informationConflict of Interest Policy. Approved May 2016 Mayo Clinic Board of Governors
Conflict of Interest Policy Approved May 2016 Mayo Clinic Board of Governors Table of Contents I. Overview... 4 A. Guiding Principles... 4 B. What is a Conflict of Interest?... 4 C. What Can Cause a Financial
More informationPHASE II OF THE FINAL STARK REGULATIONS: WHAT DO THEY MEAN FOR HEALTHCARE PROVIDERS
Kean Miller Health Care Industry Business Group PHASE II OF THE FINAL STARK REGULATIONS: WHAT DO THEY MEAN FOR HEALTHCARE PROVIDERS April 28, 2004 Linda G. Rodrigue, Esq. and Clay J. Countryman, Esq. Kean,
More informationTable of Contents. Executive Resources, LLC 2015, v. 2
2 Table of Contents I. Introduction II. Overview III. Contract Pharmacy and Arrangements IV. HRSA and 340B Data Base V. Software, Internal Control Systems and Management of Inventory VI. External Relationships
More informationDIFFERENTIAL CHARGING TO MEDICARE AND SELF-PAY AND COMMERCIAL PAYORS
overview DIFFERENTIAL CHARGING TO MEDICARE AND SELF-PAY AND COMMERCIAL PAYORS Institute on Medicare and Medicaid Payment Issues March, 2013 Andrew Ruskin, Partner Morgan, Lewis & Bockius, Washington, DC
More informationOBJECTIVITY IN RESEARCH POLICY
OBJECTIVITY IN RESEARCH POLICY This Policy addresses NCQA s responsibility for ensuring objectivity in research in accordance with 42 CFR Part 50, Subpart F Promoting Objectivity in Research, and 45 CFR
More informationU.S. v. Sulzbach: Government Theories, Potential Defenses, and Lessons Learned
U.S. v. Sulzbach: Government Theories, Potential Defenses, and Lessons Learned Presented By: David O Brien Christine Rinn Michael Paddock HOOPS 2007 - Washington, DC October 15-16 Background June 1994:
More informationCorporate Compliance Program. Intended Audience: All SEH Associates 2016 Content Expert: Lisa Frey -
Corporate Compliance Program Intended Audience: All SEH Associates 2016 Content Expert: Lisa Frey - lisa.frey@stelizabeth.com Developed 2012, reviewed Dec 2015 What is Corporate Compliance? Hospitals,
More information2014 Lathrop & Gage LLP Lathrop & Gage LLP Lathrop & Gage LLP
Legal Issues for Physician Owned Implant Manufacturer/Distribution Companies (PODs) October 24, 2014 Randal L. Schultz, Esq. 10851 Mastin Blvd, Building 82, Suite 1000 Overland Park, KS 66210-1669 913.451.5192
More informationVNSNY CORPORATE POLICY AND PROCEDURE
VNSNY CORPORATE POLICY AND PROCEDURE TITLE: APPLIES TO: PUBLIC HEALTH SERVICE (PHS) FINANCIAL CONFLICT OF INTEREST (FCOI) POLICY All VNSNY Entities, but only to VNSNY personnel who are Investigators on
More information